DE60030097D1 - Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung - Google Patents

Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung

Info

Publication number
DE60030097D1
DE60030097D1 DE60030097T DE60030097T DE60030097D1 DE 60030097 D1 DE60030097 D1 DE 60030097D1 DE 60030097 T DE60030097 T DE 60030097T DE 60030097 T DE60030097 T DE 60030097T DE 60030097 D1 DE60030097 D1 DE 60030097D1
Authority
DE
Germany
Prior art keywords
aminobenzamine
substituted
caspase inhibitors
inhibitors
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60030097T
Other languages
English (en)
Other versions
DE60030097T2 (de
Inventor
Xiong Cai
Yan Wang
Eckard Weber
B Mills
R Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Application granted granted Critical
Publication of DE60030097D1 publication Critical patent/DE60030097D1/de
Publication of DE60030097T2 publication Critical patent/DE60030097T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DE60030097T 1999-03-16 2000-03-15 Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung Expired - Fee Related DE60030097T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12467599P 1999-03-16 1999-03-16
US124675P 1999-03-16
US15838699P 1999-10-12 1999-10-12
US158386P 1999-10-12
PCT/US2000/006398 WO2000055114A1 (en) 1999-03-16 2000-03-15 Substituted 2-aminobenzamide caspase inhibitors and the use thereof

Publications (2)

Publication Number Publication Date
DE60030097D1 true DE60030097D1 (de) 2006-09-28
DE60030097T2 DE60030097T2 (de) 2007-03-08

Family

ID=26822841

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030097T Expired - Fee Related DE60030097T2 (de) 1999-03-16 2000-03-15 Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung

Country Status (10)

Country Link
US (2) US6620782B1 (de)
EP (1) EP1165490B1 (de)
JP (1) JP2002539183A (de)
KR (1) KR20010110667A (de)
CN (1) CN1346344A (de)
AT (1) ATE336480T1 (de)
AU (1) AU3876600A (de)
CA (1) CA2367340A1 (de)
DE (1) DE60030097T2 (de)
WO (1) WO2000055114A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6319955B1 (en) * 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
WO2000004914A1 (en) * 1998-07-21 2000-02-03 Cytovia, Inc. Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
CA2367340A1 (en) * 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
JP2002541237A (ja) * 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
JP2003506389A (ja) * 1999-08-06 2003-02-18 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤およびその使用
EA200200301A1 (ru) 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2001231143A1 (en) * 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
KR100858640B1 (ko) 2000-03-29 2008-09-17 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제용 카바메이트 화합물
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002060479A1 (en) * 2001-01-29 2002-08-08 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
WO2002100410A1 (en) * 2001-06-08 2002-12-19 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease
WO2003068242A1 (en) 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
AU2003225088A1 (en) * 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
EP1628674A2 (de) * 2003-05-06 2006-03-01 Cytovia, Inc. Protease-hemmer für coronaviren und sars-cov und ihre verwendung
KR20050034922A (ko) * 2003-10-10 2005-04-15 주식회사 엘지생명과학 2-알킬-4-옥소부타노일 그룹을 함유하는 케스페이즈저해제 및 그의 약제학적 조성물
SI1725548T1 (sl) * 2004-03-12 2015-05-29 Vertex Pharmaceuticals Incorporated Postopki in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze
WO2005095335A1 (ja) * 2004-03-31 2005-10-13 Kureha Corporation イリド化合物、その製造方法、除草剤および医薬品中間体としての利用
PL217743B1 (pl) 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2008108944A2 (en) 2007-03-01 2008-09-12 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
CN101919833B (zh) * 2010-07-16 2012-01-11 暨南大学 一种芳香类化合物作为制备Caspase 3抑制剂的用途
WO2012061785A2 (en) 2010-11-05 2012-05-10 Brandeis University Ice inhibiting compounds and uses thereof
EP2644606A4 (de) * 2010-11-22 2015-03-25 Hitachi Chemical Co Ltd Seltenerd-metallkomplex
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
CN106317161B (zh) * 2015-06-29 2020-05-15 深圳翰宇药业股份有限公司 一种氟甲基酮肽系列化合物的制备方法
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CN107029221A (zh) * 2017-01-26 2017-08-11 上海交通大学 胱氨酸蛋白酶抑制剂在制备防治紫外光诱导的皮肤损伤药物、保健品及各种制剂中的应用
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2381023A1 (fr) 1977-02-18 1978-09-15 Delalande Sa Nouveaux oligopeptides trifluoromethyles derives de la l-alanine, leur procede de preparation et leur application en therapeutique
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co Inc Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
EP1378573A1 (de) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin-1-beta-protease und Interleukin-1-beta-protease Inhibitoren
ATE169224T1 (de) 1992-02-21 1998-08-15 Merck & Co Inc Peptidylderivate und inhibitoren des interleukin- 1-g(b)-konvertierenden enzyms
EP0618223A3 (de) 1993-03-08 1996-06-12 Sandoz Ltd Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US6087160A (en) 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
US5435271A (en) 1993-08-19 1995-07-25 Invisible Fence Company, Inc. Multi-channel animal control device with external data communication
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
DE69711845T2 (de) 1996-09-12 2002-10-31 Idun Pharmaceuticals Inc Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften
ES2255112T3 (es) 1996-09-12 2006-06-16 Idun Pharmaceuticals, Inc. Inhibicion de apoptosis usando inhibidores de la familia de la enzima convertidora de interleucina 1-beta (ice)/ced-3.
SI20110A (sl) 1997-03-18 2000-06-30 Basf Aktiengesellschaft Metode in sestavki za moduliranje odzivnosti na kortikosteroide
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
EA200000409A1 (ru) 1997-10-10 2000-10-30 Сайтовиэ, Инк. Соединение, фармацевтическая композиция, способ ингибирования гибели клетки в одной клетке или ткани, способ лечения или снижения клеточной смерти, способ лечения или профилактики поликистозного заболевания почек или анемии/эритропоэза у животных, способ защиты органа или ткани млекопитающего от гибели клеток, способ снижения или профилактики гибели клеток в органе или ткани донора после их трансплантации, способ снижения или предотвращения гибели спермы или яйцеклеток
EP1076563B1 (de) 1998-03-16 2005-05-11 Cytovia, Inc. Dipeptid kaspase inhibitoren und deren verwendung
US6201118B1 (en) * 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
CA2367340A1 (en) * 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
JP2002541237A (ja) * 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
JP2003506389A (ja) 1999-08-06 2003-02-18 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤およびその使用
EA200200301A1 (ru) * 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
US6566338B1 (en) * 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death

Also Published As

Publication number Publication date
WO2000055114A1 (en) 2000-09-21
DE60030097T2 (de) 2007-03-08
ATE336480T1 (de) 2006-09-15
US6620782B1 (en) 2003-09-16
AU3876600A (en) 2000-10-04
KR20010110667A (ko) 2001-12-13
EP1165490B1 (de) 2006-08-16
CN1346344A (zh) 2002-04-24
CA2367340A1 (en) 2000-09-21
EP1165490A4 (de) 2002-09-18
US20030181388A1 (en) 2003-09-25
EP1165490A1 (de) 2002-01-02
JP2002539183A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
ATE336480T1 (de) Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
DE60035037D1 (de) Caspase inhibitoren und ihre verwendung
DE69925268D1 (de) Dipeptid kaspase inhibitoren und deren verwendung
ATE409688T1 (de) Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE309237T1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DK1485359T3 (da) Natriumkanalblokkere
DE60140695D1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
IS7718A (is) Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
TR200002740T2 (tr) Piperidinil ve N-Amidinopiperidinil türevleri
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
WO1999065451A3 (en) Caspases and apoptosis
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
EA200601106A1 (ru) Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
DE59901563D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
NO20055699L (no) Imidazopyridinintermediater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee